Background: Prior to direct-acting antiviral (DAA) therapy, personalised medicine played an
important role in the treatment of hepatitis C virus (HCV). Whilst simplified treatment …

The advent of highly effective and well‐tolerated direct antiviral antivirals (DAAs) has
dramatically changed the landscape of chronic hepatitis C. The effect of DAAs in older adults …

We report the synthesis and biological evaluation of a series of 4′-fluoro-2′-C-substituted
uridines. Triphosphates of the uridine analogues exhibited a potent inhibition of hepatitis C …

Chronic hepatitis C (CHC) is a major liver disease caused by the hepatitis C virus. The
current standard of care for CHC can achieve cure rates above 95%; however, the drugs in …

Introduction: Treatments for hepatitis C virus (HCV) infection have advanced rapidly in the
last decade. Pegylated interferon alpha 2a (PEG-IFN alpha 2a) alone, in combination with …

Hepatitis C virus (HCV) treatments have dramatically progressed from poorly tolerated,
moderately successful interferon-based therapies to highly effective all-oral interferon-free …

Enhancing treatment uptake for hepatitis C to achieve the elimination goals set by the World
Health Organization could be achieved by reducing the treatment duration. The aim of this …

Hepatocellular carcinoma (HCC) is a serious complication of hepatitis C virus (HCV)
infection. Sustained virologic response (SVR) for HCV is associated with a reduction in …

Despite the lack of precise mechanisms of action, a growing number of studies suggests that
gut microbiota is involved in a great number of physiological functions of the human …

Direct-acting antiviral (DAA) treatment for 8 weeks has a sustained virological response rate
in adults with chronic hepatitis C. We have conducted a systematic review and meta …